

Recombinant Porcine Interleukin-8/CXCL8 (Porcine IL-8/CXCL8)

Product Information

| Product Name | Cat# | Size |
|--|-----------|--------|
| Recombinant Porcine Interleukin-8/CXCL8 (Porcine IL-8/CXCL8) | 90903ES10 | 10 μg |
| | 90903ES60 | 100 μg |
| | 90903ES76 | 500 μg |

Product Description

Interleukin-8 (IL-8), also known as CXCL8, GCP-1, and NAP-1, is a widely expressed proinflammatory member of the CXC family of chemokines. This 8-9 kDa chemokine circulates as a monomer, homodimer, and heterodimer with CXCL4/PF4. Its oligomerization is modulated by interactions with matrix and cell surface glycosaminoglycans (GAGs). Mature porcine CXCL8 shares 82%, 78%, and 65% amino acid (aa) sequence identiity with canine, feline, and human CXCL8. There is no CXCL8 gene counterpart in rodent. N-terminal truncation of CXCL8 by multiple proteases generates a range of shorter forms. The bioactivity of CXCL8 is regulated by these truncations and also by CXCL8 citrullination. CXCL8 effects are mediated through CXCR1/IL-8 RA, which is also used by CXCL6, and through CXCR2/IL-8 RB, which is used by multiple CXC chemokines. These receptors associate into functional homodimers and heterodimers with each other. Through both CXCR1 and CXCR2, CXCL8 promotes neutrophil adhesion to the vascular endothelium and migration to sites of inflammation. It triggers the antimicrobial activation of neutrophils through CXCR1. CXCL8 also binds to Serpin A1/alpha-1 Antitrypsin, and this prevents CXCL8 interaction with CXCR1. CXCL8 is up-regulated in atherosclerotic lesions and other cardiac pathologies where it exacerbates inflammatory tissue damage. In addition, it induces VEGF expression, vascular endothelial cell proliferation, angiogenesis, and tumor cell invasiveness.

Product Properties

| Synonyms | (Ser-IL-8)72, GCP/IL-8 protein I, IL8/NAP1 form III, LYNAP, MDNCF-c, NAF | | |
|---------------------|---|--|--|
| Accession | P26894 | | |
| GeneID | 396880 | | |
| Source | E.coli-derived Porcine IL-8/CXCL8, Ala26-Gln103. | | |
| Molecular Weight | Approximately 9.1 kDa. | | |
| AA Sequence | ARVSAELRCQ CINTHSTPFH PKFIKELRVI ESGPHCENSE IIVKLVNGKE VCLDPKEKWV | | |
| | QKVVQIFLKR TEKQQQQQ | | |
| Tag | None | | |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. | | |
| Purity | > 95% by SDS-PAGE and HPLC analyses. | | |
| Biological Activity | The biological activity determined by a chemotaxis bioassay using human peripheral blood neutrophils is | | |
| | in a concentration range of 20-200 ng/mL. Fully biologically active when compared to standard. | | |
| Endotoxin | < 1.0 EU per 1µg of the protein by the LAL method. | | |
| | | | |

www.yeasen.com Page 1 of 2

Yeasen Biotechnology (Shanghai) Co., Ltd.
Hotline: 400-6111-883

E-mail: order@yeasen.com

Reconstitution

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at \leq -20°C. Further dilutions should be made in appropriate buffered solutions.

Shipping and Storage

The products are shipped with ice pack and can be stored at -20°C to -80°C for 1 year.

Recommend to aliquot the protein into smaller quantities when first used and avoid repeated freeze-thaw cycles.

Cautions

- 1. Avoid repeated freeze-thaw cycles.
- 2. For your safety and health, please wear lab coats and disposable gloves for operation.
- 3. For research use only!

www.yeasen.com Page 2 of 2